VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Sunday morning. The firm issued a sell rating on the stock.

A number of other research analysts have also recently weighed in on VNRX. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Thursday, February 6th.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.61 on Friday. The stock has a market capitalization of $56.16 million, a P/E ratio of -1.68 and a beta of 1.20. The company has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.65. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.10.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the acquisition, the director now directly owns 617,085 shares in the company, valued at $351,738.45. This represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock worth $204,212 in the last 90 days. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

Institutional investors have recently modified their holdings of the stock. Ground Swell Capital LLC lifted its position in shares of VolitionRx by 78.8% during the 3rd quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock worth $28,000 after buying an additional 20,249 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx during the 4th quarter worth approximately $29,000. Millennium Management LLC purchased a new stake in shares of VolitionRx during the 4th quarter worth approximately $36,000. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.